Skip to main content

Table 4 Most frequent (≥10%) adverse events reported during treatment

From: Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)

  Abiraterone acetate plus prednisone
(N = 100)
Cabazitaxel plus prednisone
(N = 44)
Adverse event Mild Moderate Severe Total Mild Moderate Severe Total
Asthenia 16 (16.0) 14 (14.0) 1 (1.0) 31 (31.0) 14 (31.8) 8 (18.2) 2 (4.5) 24 (54.5)
Pain 14 (14.0) 11 (11.0) 3 (3.0) 28 (28.0) 3 (6.8) 3 (6.8) 3 (6.8) 9 (20.5)
Anemia 7 7.0 7 7.0 1 (1.0) 15 (15.0) 6 (13.6) 3 (6.8) 1 (2.3) 10 (22.7)
Edema 13 (13.0) 2 (2.0) 0 (0.0) 15 (15.0) 3 (6.8) 1 (2.3) 2 (4.5) 6 (13.6)
Vomiting 7 (7.0) 0 (0.0) 2 (2.0) 9 (9.0) 4 (9.1) 1 (2.3) 0 (0.0) 5 (11.4)
Diarrhea 6 (6.0) 2 (2.0) 0 (0.0) 8 (8.0) 7 (15.9) 5 (11.4) 2 (4.5) 14 (31.8)
Anorexia 6 (6.0) 1 (1.0) 0 (0.0) 7 (7.0) 5 (11.4) 3 (6.8) 1 (2.3) 9 (20.5)
Urinary infection 1 (1.0) 5 (5.0) 1 (1.0) 7 (7.0) 1 (2.3) 3 (6.8) 2 (4.5) 6 (13.6)